映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09606 映恩生物-B

已收盘 09-24 16:08:31

198.300

-16.700

-7.77%

最高211.400	最低196.500	成交量86.95万
今开210.800	昨收215.000	日振幅6.93%
总市值180.12亿	流通市值180.12亿	总股本9,083万
成交额1.75亿	换手率0.96%	流通股本9,083万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":198.3,"timestamp":1790237311009,"preClose":215,"halted":0,"volume":869500,"delay":0,"changeRate":-0.07767441860465112,"floatShares":90833600,"shares":90833600,"eps":-46.47385947438179,"marketStatus":"已收盘","change":-16.7,"latestTime":"09-24 16:08:31","open":210.8,"high":211.4,"low":196.5,"amount":175196710,"amplitude":0.069302,"askPrice":198.4,"askSize":200,"bidPrice":198.3,"bidSize":900,"shortable":3,"etf":0,"ttmEps":-18.81623697077023,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790299800000},"marketStatusCode":5,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":215,"openAndCloseTimeList":[[1790213400000,1790222400000],[1790226000000,1790236800000]],"volumeRatio":0.793343,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09606","defaultTab":"news","newsList":[{"id":"1147890373","title":"异动解读｜映恩生物-B盘中下跌5.02%，报204.2港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1147890373","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147890373?lang=zh_cn&edition=full","pubTime":"2026-09-24 10:09","pubTimestamp":1790215779,"startTime":"0","endTime":"0","summary":"9月24日，映恩生物-B盘中下跌5.02%，报204.2港元/股，成交额3023.1万港元。映恩生物-B所在的生物科技行业整体走弱，个股中，康方生物跌3.44%，信达生物跌3.58%，百济神州跌1.47%，荣昌生物跌5.58%，三生制药跌3.64%。映恩生物是一家主要从事临床阶段生物制药的投资控股公司，致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物创新药物，主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310等，覆盖子宫内膜癌、乳腺癌、小细胞肺癌等多个适应症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188227323","title":"创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188227323","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188227323?lang=zh_cn&edition=full","pubTime":"2026-09-23 11:01","pubTimestamp":1790132509,"startTime":"0","endTime":"0","summary":"9月23日，创新药概念走高，云顶新耀、药明巨诺-B涨逾5%，金斯瑞生物科技涨逾4%，康方生物、诺诚健华涨逾3%，基石药业涨逾2%，百济神州、药明生物、君实生物涨逾1%，信达生物跟涨。9月12-15日2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3 ADC等成为焦点；与此同时，2026年国家医保目录谈判收官，商保创新药目录同步推进，支付端改革预期升温，\"出海商业化+支付改善\"的产业逻辑持续强化。","market":"hk","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","02269","03347","02359","03759","06622","06978","06996","00241","09606","09688","09966","06606","09995","02137","06618","02268","01801"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170311123","title":"异动解读｜映恩生物-B盘中上涨5.24%，DB-1311联合方案一线SCLC ORR达92.3%持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1170311123","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170311123?lang=zh_cn&edition=full","pubTime":"2026-09-18 11:31","pubTimestamp":1789702306,"startTime":"0","endTime":"0","summary":"9月18日，映恩生物-B盘中上涨5.24%，报192.9港元，成交额1.03亿港元。消息面上，近日世界肺癌大会更新了映恩生物与BioNTech共同开发的B7-H3 ADC DB-1311/BNT324联合PD-L1×VEGF-A双抗Pumitamig治疗晚期肺癌的Ib/II期临床数据：71例可评估小细胞肺癌患者整体客观缓解率达70.4%，其中一线ORR高达92.3%、二线77.3%、三线及以上52.4%，数据表现亮眼，持续提振市场情绪。映恩生物是一家临床阶段生物制药公司，致力于研发覆盖肿瘤与自身免疫性疾病的抗体偶联药物创新疗法。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物盘中上涨，一线肺癌数据亮眼","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100752322","title":"异动解读｜映恩生物-B盘中上涨10.55%，DB-1311联合方案一线SCLC ORR达92.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100752322","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100752322?lang=zh_cn&edition=full","pubTime":"2026-09-14 14:50","pubTimestamp":1789368640,"startTime":"0","endTime":"0","summary":"9月14日，映恩生物-B盘中上涨10.55%，报186.5港元，成交额1.87亿港元。消息面上，世界肺癌大会更新了映恩生物与BioNTech共同开发的B7-H3 ADC DB-1311/BNT324联合PD-L1×VEGF-A双抗Pumitamig治疗晚期肺癌的Ib/II期临床数据：截至7月7日，71例可评估小细胞肺癌患者整体客观缓解率为70.4%，其中一线ORR高达92.3%、二线77.3%、三线及以上52.4%，数据表现亮眼。映恩生物是一家临床阶段生物制药公司，致力于研发抗体偶联药物，覆盖肿瘤与自身免疫性疾病领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物大涨，一线小细胞肺癌数据亮眼","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667658657","title":"港股异动 | 映恩生物-B涨超9%，DB-1311联用Pumitamig WCLC摘要披露，一线SCLC ORR达92.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667658657","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667658657?lang=zh_cn&edition=full","pubTime":"2026-09-14 14:38","pubTimestamp":1789367907,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B涨超9%，截至发稿，涨8.48%，报183港元，成交额1.65亿港元。消息面上，世界肺癌大会更新了映恩生物与BioNTech共同开发的B7-H3 ADC BNT324/DB-1311联合PD-L1×VEGF-A双抗Pumitamig治疗晚期肺癌的Ib/II期数据：截至2026年7月7日，71例可评估小细胞肺癌患者整体客观缓解率为70.4%，其中一线92.3%、二线77.3%、三线及以上52.4%。","market":"fut","thumbnail":"https://community-static.tradeup.com/news/b772ac54294987140db862d7556db12e","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/b772ac54294987140db862d7556db12e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495543.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物 DB-1311联用Pumitamig WCLC摘要披露，一线SCLC ORR达92.3%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","HK0000252152.HKD","BK1161","KCAI","BK4585","VXUS","ORR","LU2543165471.USD","HK0000500386.USD","09606","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144991606","title":"异动解读｜映恩生物-B盘中下跌5.38%，生物科技板块集体承压叠加中期业绩承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1144991606","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144991606?lang=zh_cn&edition=full","pubTime":"2026-09-10 10:20","pubTimestamp":1789006810,"startTime":"0","endTime":"0","summary":"9月10日，映恩生物-B盘中下跌5.38%，报174.0港元，成交额7780.66万港元。消息面上，公司此前披露的中期业绩显示，上半年营收2.19亿元，较上年同期的12.29亿元大幅下滑，经调整净亏损6.27亿元，经营活动现金流由上年同期净流入5.90亿元转为净流出4.24亿元。此外，生物科技板块今日整体走弱，行业个股中云顶新耀跌7.82%、三生制药跌3.16%、信达生物跌2.49%、康方生物跌0.79%、百济神州跌0.67%，板块系统性回调亦对股价形成拖累。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"映恩生物盘中下跌，生物科技板块集体承压","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161734352","title":"映恩生物-B：DualityBio Ltd.增持，好仓比例升至7.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=1161734352","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161734352?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:52","pubTimestamp":1788861153,"startTime":"0","endTime":"0","summary":"DualityBio Ltd.于2026年9月2日以每股均价174.054港元买入映恩生物-B股份1.00万股，涉资约174.05万港元。DualityBio Ltd.此次增持前持有映恩生物-B好仓655.50万股，占比7.18%；增持后持股量为656.50万股，好仓比例升至7.19%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187354305","title":"映恩生物-B：DualityBio Ltd.增持，好仓比例升至7.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187354305","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187354305?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:16","pubTimestamp":1788859002,"startTime":"0","endTime":"0","summary":"DualityBio Ltd.于2026年9月3日以每股均价184.149港元买入映恩生物-B股份1.00万股，涉资约184.15万港元。DualityBio Ltd.此次增持前持有映恩生物-B好仓656.50万股，占比7.19%；增持后持股量为657.50万股，好仓比例升至7.2%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665432393","title":"港股异动 | 映恩生物-B(09606)尾盘涨超4% 与罗氏合作BD新突破 潜在里程碑金额超10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665432393","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665432393?lang=zh_cn&edition=full","pubTime":"2026-09-08 15:58","pubTimestamp":1788854320,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B尾盘涨超4%。截至发稿，涨3.56%，报186.4港元，成交额1.94亿港元。消息面上，近日，映恩生物与罗氏集团旗下Genentech签署合作许可协议，依托公司DUPAC平台开发多款肿瘤适应症下一代ADC药物。根据合作协议，映恩生物将收取4500万美元的首付款，并有资格就所有合作项目收取总额超过10亿美元的潜在开发、监管及商业化里程碑付款。同时，公司已与多家全球药企达成合作，首付款、里程碑付款及潜在销售分成有望构成长期收入来源。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493292.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","HK0000500386.USD","VXUS","LU2543165471.USD","BK1161","HK0000252160.HKD","HK0000252152.HKD","BK4588","BK4585","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665323932","title":"港股异动 | 映恩生物-B(09606.HK)尾盘涨超4% 与罗氏合作BD新突破 潜在里程碑金额超10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323932","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665323932?lang=zh_cn&edition=full","pubTime":"2026-09-08 15:58","pubTimestamp":1788854320,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000252152.HKD","LU2543165471.USD","HK0000252160.HKD","BK1161","HK0000500386.USD","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665191233","title":"主席兼首席执行官朱忠远连续两日增持映恩生物-B(09606)共计2万股 涉资约358.2万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665191233","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665191233?lang=zh_cn&edition=full","pubTime":"2026-09-07 19:23","pubTimestamp":1788780207,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月2日-3日，主席兼首席执行官朱忠远连续两日增持映恩生物-B(09606)股份，合计2万股，每股平均作价约179.1港元，总金额约为358.2万港元。增持后最新持股数目约为1603.97万股，最新持股比例为17.58%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","BK1161","HK0000252152.HKD","LU2543165471.USD","09606","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128608877","title":"映恩生物-B：朱忠远增持，好仓比例升至17.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=1128608877","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128608877?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:14","pubTimestamp":1788772467,"startTime":"0","endTime":"0","summary":"朱忠远于2026年9月2日以每股均价174.054港元买入映恩生物-B股份1.00万股，涉资约174.05万港元。朱忠远此次增持前持有映恩生物-B好仓1601.97万股，占比17.56%；增持后持股量为1602.97万股，好仓比例升至17.57%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157586803","title":"映恩生物-B更新8月股份变动月报表，注册股本维持20,000美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1157586803","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157586803?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:54","pubTimestamp":1788512040,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年9月4日发布截至2026年8月31日的月度股份变动报告。公告显示，公司法定/注册股本维持在200,000,000股普通股不变，每股面值0.0001美元，总额20,000美元，未见调整。截至2026年8月31日，公司已发行股份从月初的90,824,214股增至90,833,614股，新增9,400股；库存股份数目则维持在400,100股不变。报告期末已发行股份总数为91,233,714股，符合相应的公众持股量要求。公告显示，公司重申将继续遵守香港联合交易所有限公司《上市规则》及相关法律法规的要求。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664824188","title":"港股异动 | 映恩生物-B(09606)午后涨超6% BD合作交易总规模超70亿美元 公司探索转为在美共同开发方","url":"https://stock-news.laohu8.com/highlight/detail?id=2664824188","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664824188?lang=zh_cn&edition=full","pubTime":"2026-09-03 14:58","pubTimestamp":1788418738,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，映恩生物-B午后涨超6%。截至发稿，涨5.74%，报186.1港元，成交额1.43亿港元。华创证券发布研报称，映恩已与国内外7家全球制药公司和创新药企就6个分子及DUPAC创新载荷平台达成合作/合作披露交易总金额超70亿美元，目前仅收到约5.5亿美元首付款与里程碑款项，超65亿美金未确认里程碑收入及药物上市后高个位数至低双位数的销售分成为后续持续现金流流入提供坚实基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000500386.USD","BK4588","BK1161","HK0000252160.HKD","LU2543165471.USD","09606","HK0000252152.HKD","VXUS","KCAI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185103683","title":"异动解读｜映恩生物-B盘中上涨5.45%，多家机构维持买入评级叠加超跌反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1185103683","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185103683?lang=zh_cn&edition=full","pubTime":"2026-09-03 14:29","pubTimestamp":1788416991,"startTime":"0","endTime":"0","summary":"9月3日，映恩生物-B盘中上涨5.45%，报185.6港元/股，成交额1.23亿港元。消息面上，招银国际9月2日发布研报维持公司\"买入\"评级，目标价284.50港元，继续看好核心管线Elfe-D在mCRPC领域的重磅潜力。此前瑞银亦首次覆盖给予\"买入\"评级，目标价320港元，东吴证券、招商证券等机构同步看多。此前公司因中期业绩营收同比大幅下滑、经调整净利转亏等因素，股价连续两日累计跌超10%，本次上涨或与多家机构看多共振下的超跌修复有关。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物获多家机构看多，股价超跌反弹上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664896872","title":"【券商聚焦】招银国际维持映恩生物（09606）“买入”评级 继续看好Elfe-D在mCRPC领域的重磅潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2664896872","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664896872?lang=zh_cn&edition=full","pubTime":"2026-09-02 13:10","pubTimestamp":1788325841,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际研报指，继续认为，DB-1311/BNT324 是映恩生物最核心的价值驱动，看好其在mCRPC领域的重磅品种潜力。核心管线方面，该机构继续认为mCRPC仍是Elfe-D最重要的估值锚点。ve mCRPC患者、对比docetaxel的全球Phase 3研究，临床推进进一步提速。继续看好Elfe-D在mCRPC领域的重磅潜力，以及ADC + IO2.0联合策略带来的增量空间。考虑到B7-H3 ADC赛道竞争加剧，该机构将公司目标价下调至284.50港元，维持“买入”评级。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990427","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113854323","title":"异动解读｜映恩生物-B盘中下跌7.29%，上半年营收大幅缩水且经调整净利转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=1113854323","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113854323?lang=zh_cn&edition=full","pubTime":"2026-08-31 15:05","pubTimestamp":1788159916,"startTime":"0","endTime":"0","summary":"8月31日，映恩生物-B盘中下跌7.29%，报185.6港元/股，成交额2.82亿港元。经调整净利润由上年同期盈利1.46亿元转为亏损6.27亿元，经营现金流从流入5.90亿元转为净流出4.24亿元，研发开支同比增长73.64%至6.07亿元。此外，生物科技板块整体承压，信达生物跌3.91%，康方生物跌5.24%，百济神州跌3.92%，三生制药跌4.25%，云顶新耀跌6.41%，行业情绪偏弱进一步加剧个股跌幅。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"映恩生物盘中异动，营收骤降净利转亏","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662064730","title":"映恩生物-B(09606.HK)发布中期业绩，研究与开发开支6.07亿元 同比增加73.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662064730","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662064730?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:50","pubTimestamp":1787914238,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","LU2543165471.USD","09606","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149809359","title":"映恩生物-B2026年上半年营收2.19亿元 经调整净亏损6.27亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149809359","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149809359?lang=zh_cn&edition=full","pubTime":"2026-08-28 18:37","pubTimestamp":1787913436,"startTime":"0","endTime":"0","summary":"映恩生物-B在公告中披露，截至2026年6月30日止六个月，公司实现营收2.19亿元，较上年同期的12.29亿元出现大幅下滑。管理层表示，主要由于行使DB-1311/BNT324美国市场独家成本及利润/亏损分担选择权时产生一次性影响，使收入扣减约2.91亿元，同时期内可确认的首付款及里程碑收入也同比减少。非公认会计准则口径（经调整）净利润方面，由上年同期的1.46亿元转为亏损6.27亿元。经营活动现金流从去年同期流入5.90亿元转为本期净流出4.24亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"映恩生物-B2026年上半年营收2.19亿元 经调整净亏损6.27亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109370447","title":"映恩生物-B携手基因泰克，基于DUPAC新型载荷平台共研下一代抗体偶联药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1109370447","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109370447?lang=zh_cn&edition=full","pubTime":"2026-08-28 12:10","pubTimestamp":1787890236,"startTime":"0","endTime":"0","summary":"映恩生物-B近日宣布，已与罗氏旗下基因泰克达成一项全球合作与许可协议。双方将依托映恩生物自主研发的DUPAC创新载荷平台，共同推进新一代抗体偶联药物的研发工作。这一合作标志着映恩生物在ADC领域的创新实力获得国际制药巨头的认可。映恩生物此次与基因泰克的联手，不仅为其技术平台提供了国际化验证机会，也为公司未来管线拓展奠定了坚实基础。随着更多类似合作的落地，国内ADC药物研发水平有望迈上新台阶。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252160.HKD","HK0000500386.USD","09606","HK0000252152.HKD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dualitybiologics.com","stockEarnings":[{"period":"1week","weight":0.2065},{"period":"1month","weight":0.1346},{"period":"3month","weight":0.279},{"period":"6month","weight":-0.2435},{"period":"1year","weight":-0.4145},{"period":"ytd","weight":-0.279}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":-0.0268},{"period":"3month","weight":0.0761},{"period":"6month","weight":-0.0047},{"period":"1year","weight":-0.0507},{"period":"ytd","weight":-0.0311}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"映恩生物是一家主要从事临床阶段生物制药的投资控股公司。该公司致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物。该公司的主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310、DB-1305/BNT325、DB-1419和DB-2304。该公司的产品主要用于靶向治疗子宫内膜癌（EC）、乳腺癌（BC）、小细胞肺癌（SCLC）、去势抵抗性前列腺癌（CRPC）、食管鳞状细胞癌（ESCC）及头颈部鳞状细胞癌（HNSCC）。该公司主要在国内和国外市场开展业务。","exchange":"SEHK","name":"映恩生物-B","nameEN":"DUALITYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"映恩生物-B,09606,映恩生物-B股票,映恩生物-B股票老虎,映恩生物-B股票老虎国际,映恩生物-B行情,映恩生物-B股票行情,映恩生物-B股价,映恩生物-B股市,映恩生物-B股票价格,映恩生物-B股票交易,映恩生物-B股票购买,映恩生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}